Home › All Companies › BIOA › Annual Report

BioAge Labs, Inc. (BIOA) — Annual Report

AI-Powered SEC Filing Analysis

← All BIOA filings
Latest Annual Report Filed: 2026-03-24

Key Insights

  • BioAge Labs, Inc. (BIOA) has entered into a collaborative arrangement with Novartis Pharma AG, which could provide additional revenue streams and strategic partnerships.
  • The company has secured a loan and security agreement with SVB Innovative Credit Growth Fund IX, LP and Innovative Credit Growth Fund VIII, ALP, providing additional financing to fund operations.
  • BioAge Labs has implemented an at-the-market (ATM) sales agreement with Leerink Partners LLC to raise additional capital through equity offerings.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for BioAge Labs, Inc.

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.